litlas
ログインアカウント作成

Peter J. Neumann

1994–2024 年に発表

119
論文数
21,660
被引用数
79
h 指数
117
i10 指数

被引用数

Peter J. Neumann の年別被引用数1993 年: 被引用 1 件1994 年: 被引用 1 件1995 年: 被引用 5 件1996 年: 被引用 4 件1997 年: 被引用 10 件1998 年: 被引用 3 件1999 年: 被引用 8 件2000 年: 被引用 26 件2001 年: 被引用 49 件2002 年: 被引用 58 件2003 年: 被引用 67 件2004 年: 被引用 79 件2005 年: 被引用 89 件2006 年: 被引用 99 件2007 年: 被引用 74 件2008 年: 被引用 86 件2009 年: 被引用 83 件2010 年: 被引用 88 件2011 年: 被引用 77 件2012 年: 被引用 79 件2013 年: 被引用 88 件2014 年: 被引用 88 件2015 年: 被引用 82 件2016 年: 被引用 112 件2017 年: 被引用 124 件2018 年: 被引用 164 件2019 年: 被引用 637 件2020 年: 被引用 891 件2021 年: 被引用 712 件2022 年: 被引用 479 件2023 年: 被引用 313 件2024 年: 被引用 541 件2025 年: 被引用 222 件2026 年: 被引用 12 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,589 件、この内訳の 32.8%イギリス: 引用元論文 810 件、この内訳の 10.2%カナダ: 引用元論文 508 件、この内訳の 6.4%オーストラリア: 引用元論文 338 件、この内訳の 4.3%オランダ: 引用元論文 337 件、この内訳の 4.3%中国: 引用元論文 320 件、この内訳の 4%ドイツ: 引用元論文 284 件、この内訳の 3.6%イタリア: 引用元論文 232 件、この内訳の 2.9%スイス: 引用元論文 164 件、この内訳の 2.1%フランス: 引用元論文 155 件、この内訳の 2%スペイン: 引用元論文 151 件、この内訳の 1.9%スウェーデン: 引用元論文 147 件、この内訳の 1.9%
0%32.8%その他 23.6%

機関

分野

  • Medicine63.3%
  • Economics, Econometrics and Finance15.8%
  • Health Professions4.9%
  • Biochemistry, Genetics and Molecular Biology3.9%
  • Psychology1.9%
  • Mathematics1.4%
  • その他8.8%

トピック

  • Health Systems, Economic Evaluations, Quality of Life7.5%
  • Dementia and Cognitive Impairment Research3%
  • Healthcare cost, quality, practices1.8%
  • Economic and Financial Impacts of Cancer1.7%
  • Pharmaceutical Economics and Policy1.4%
  • Healthcare Policy and Management1.3%
  • その他83.3%

共著者

全論文

検索で開く
  1. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

    著者: Gillian D Sanders, Peter J. Neumann, Anirban Basu, Dan W. Brock, David Feeny, Murray Krahn, Karen M. Kuntz, David O. Meltzer, Douglas K Owens, Lisa A. Prosser, Joshua A. Salomon, Mark Sculpher, Thomas A Trikalinos, Louise B. Russell, Joanna E. Siegel, Théodore G. Ganiats - JAMA 2016 被引用: 3,012

  2. Updating Cost-Effectiveness — The Curious Resilience of the 50,000-per-QALY Threshold

    著者: Peter J. Neumann, Joshua T. Cohen, Milton C. Weinstein - New England Journal of Medicine 2014 被引用: 2,250

  3. Cost-effectiveness Thresholds Used by Study Authors, 1990-2021

    著者: Peter J. Neumann, David D. Kim - JAMA 2023 被引用: 155

  4. Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018

    著者: David D. Kim, Madison C. Silver, Natalia Kunst, Joshua T. Cohen, Daniel A. Ollendorf, Peter J. Neumann - PharmacoEconomics 2020 被引用: 272

  5. Economic Impact of Childhood and Adult Attention-Deficit/Hyperactivity Disorder in the United States

    著者: Jalpa A. Doshi, Paul Hodgkins, Jennifer Kahle, Vanja Sikirica, Michael J. Cangelosi, Juliana Setyawan, M. Haim Erder, Peter J. Neumann - Journal of the American Academy of Child & Adolescent Psychiatry 2012 被引用: 435

  6. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma

    著者: Christina Hackl, Peter J. Neumann, Michael Gerken, Martin Loss, Monika Klinkhammer‐Schalke, Hans J. Schlitt - BMC Cancer 2014 被引用: 329

  7. Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report

    著者: Louis P. Garrison, Peter J. Neumann, Pennifer Erickson, Deborah A. Marshall, C. Daniel Mullins - Value in Health 2007 被引用: 705

  8. The influence of time horizon on results of cost-effectiveness analyses

    著者: David D. Kim, Colby Wilkinson, Elle Pope, James D. Chambers, Joshua T. Cohen, Peter J. Neumann - Expert Review of Pharmacoeconomics & Outcomes Research 2017 被引用: 98

  9. Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk

    著者: Iris Lin, Jennifer Sung, Robert J. Sanchez, Usha G. Mallya, Mark I. Friedman, Mary Panaccio, Andrew Koren, Peter J. Neumann, Joseph Menzin - Journal of Managed Care & Specialty Pharmacy 2016 被引用: 90

  10. Racial and Ethnic Differences in Hospice Use and Hospitalizations at End-of-Life Among Medicare Beneficiaries With Dementia

    著者: Pei‐Jung Lin, Yingying Zhu, Natalia Olchanski, Joshua T. Cohen, Peter J. Neumann, Jessica D. Faul, Howard Fillit, Karen M. Freund - JAMA Network Open 2022 被引用: 69

  11. Developing Criteria for Health Economic Quality Evaluation Tool

    著者: David D. Kim, A. Lauren, Patricia G. Synnott, Tara A. Lavelle, Lisa A. Prosser, John B. Wong, Peter J. Neumann - Value in Health 2023 被引用: 64

  12. Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions

    著者: Tara A. Lavelle, Xue Feng, Marlena Keisler, Joshua T. Cohen, Peter J. Neumann, Daryl Prichard, Brock E. Schroeder, Daria Salyakina, Paula S. Espinal, Samuel B Weidner, Jill L. Maron - Genetics in Medicine 2022 被引用: 63

  13. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies

    著者: Ashley A. Leech, David D. Kim, Joshua T. Cohen, Peter J. Neumann - Value in Health 2018 被引用: 179

  14. Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders

    著者: Pei‐Jung Lin, Howard Fillit, Joshua T. Cohen, Peter J. Neumann - Alzheimer s & Dementia 2013 被引用: 140

  15. Prevalence and Impact of Medical Comorbidity in Alzheimer's Disease

    著者: P. Murali Doraiswamy, José de León, Jeffrey L. Cummings, Deborah B. Marin, Peter J. Neumann - The Journals of Gerontology Series A 2002 被引用: 267

  16. An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report [2]

    著者: Louis P. Garrison, Mark V. Pauly, Richard J. Willke, Peter J. Neumann - Value in Health 2018 被引用: 187

  17. Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis

    著者: Pei‐Jung Lin, Yue Zhong, Howard Fillit, Er Chen, Peter J. Neumann - Journal of the American Geriatrics Society 2016 被引用: 133

  18. Lethality of Alzheimer Disease and Its Impact on Nursing Home Placement

    著者: H. Michael Arrighi, Peter J. Neumann, Ivan Lieberburg, Raymond J. Townsend - Alzheimer Disease & Associated Disorders 2010 被引用: 121

  19. The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis

    著者: Peter J. Neumann, Louis P. Garrison, Richard J. Willke - Value in Health 2022 被引用: 86

  20. Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs

    著者: James D. Chambers, Madison C. Silver, Flora Berklein, Joshua T. Cohen, Peter J. Neumann - Journal of General Internal Medicine 2020 被引用: 54

  21. Racial and Ethnic Differences in Knowledge About One's Dementia Status

    著者: Pei‐Jung Lin, Joanna Emerson, Jessica D. Faul, Joshua T. Cohen, Peter J. Neumann, Howard Fillit, Allan T. Daly, Nikoletta M. Margaretos, Karen M. Freund - Journal of the American Geriatrics Society 2020 被引用: 46

  22. Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy

    著者: Michael Drummond, Peter J. Neumann, Sean D. Sullivan, Frank-Ulrich Fricke, Sean Tunis, Omar Dabbous, Mondher Toumi - Value in Health 2019 被引用: 92

  23. Cost-Effectiveness of PET in the Diagnosis of Alzheimer Disease

    著者: Pamela M. McMahon, S Araki, Eileen A. Sandberg, Peter J. Neumann, G. Scott Gazelle - Radiology 2003 被引用: 82

  24. Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES

    著者: Joshua J. Ofman, Sean D. Sullivan, Peter J. Neumann, Chiun‐Fang Chiou, James M. Henning, Sally Wade, Joel W. Hay - Journal of Managed Care Pharmacy 2003 被引用: 366